Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
N Suryadevara, S Shrihari, P Gilchuk, LA VanBlargan… - Cell, 2021 - cell.com
Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
X Chi, R Yan, J Zhang, G Zhang, Y Zhang, M Hao… - Science, 2020 - science.org
Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein
prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike …
prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike …
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site
T Onodera, S Kita, Y Adachi, S Moriyama, A Sato… - Immunity, 2021 - cell.com
Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
[HTML][HTML] Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …
Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines
Y Valdes-Balbin, D Santana-Mederos… - ACS central …, 2021 - ACS Publications
The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …